• Users Online: 612
  • Print this page
  • Email this page
Year : 2015  |  Volume : 5  |  Issue : 3  |  Page : 109-113

Autologous serum therapy in recalcitrant laser-assisted in situ keratomileusis-induced neurotrophic epitheliopathy

1 Department of Ophthalmology, National University Hospital, Taipei, Taiwan
2 Nobel Eye Clinic, Taipei, Taiwan
3 Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan
4 Department of Ophthalmology, National University Hospital, Taipei; Institute of Clinical Medicine, China Medical University, Taichung, Taiwan

Correspondence Address:
I-Jong Wang
Department of Ophthalmology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei
Shwu-Huey Lee
Department of Ophthalmology, Cathay General Hospital, 280 Renai Rd. Sec.4, Taipei
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.tjo.2015.05.004

Rights and Permissions

Background/Purpose: To evaluate the efficacy of autologous serum eye drops for patients with recalcitrant laser-assisted in situ keratomileusis (LASIK)-induced neurotrophic epitheliopathy (LINE) unresponsive to conventional treatment, and to determine the possible predisposing risk factors of these patients. Methods: We enrolled 10 consecutive patients (20 eyes) undergoing femtosecond-assisted myopic LASIK surgery presenting with recalcitrant LINE for > 1 year. Another 340 patients (713 eyes) receiving femtosecond-assisted myopic LASIK without recalcitrant LINE were set as controls. Possible risk factors associated with recalcitrant LINE were investigated. Twenty percent autologous serum treatment was prescribed to 20 eyes. The efficacy of autologous serum was assessed with ocular surface conditions, tear function, and the change of best-corrected visual acuity. Results: Age older than 30 years [odds ratio (OR) = 7.74; 95% confidence interval (CI), 1.74–34.50], flap thickness < 110 μm (OR = 3.47; 95% CI, 1.22–9.73), and a flap diameter < 8.5 mm (OR = 5.38; 95% CI, 1.95–14.85) pose higher risks in femtosecond laser-assisted myopic LASIK. All eyes (100%) achieved remission after autologous serum treatment. The visual acuity before treatment was 0.49 ± 0.41 in LogMAR, and the visual acuity after treatment was 0.14 ± 0.22 in LogMAR. Time to achieve remission was 8.26 ± 11.87 weeks. Mean relapse-free survival after discontinuing autologous serum was 47 weeks. Conclusion: Risk factors of recalcitrant LINE in femtosecond laser-assisted myopic LASIK were identified as older age, a thinner flap (<110 μm), and a small flap diameter (<8.5 mm). Autologous serum eye drops can effectively improve corneal surface conditions and postoperative visual acuity.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded79    
    Comments [Add]    
    Cited by others 3    

Recommend this journal